Teva Pharmaceutical Industries Ltd Rises On Revised Forecasts
Teva Pharmaceutical Industries Ltd., which is working toward a $40.5 billion acquisition of Allergan PLC’s generics unit, on Tuesday raised its second-quarter financial guidance. About 14.49 million shares have already exchanged hands by now, compared to the average daily trading volume of 5.11 million shares.
Teva shares rose 2.7 percent to $53.86 in NY trading, and Allergan gained 1.6 percent to $243.44. The PEG ratio is used to determine a stock’s value while taking the company’s earnings growth into account, and is considered to provide a more complete picture than the P/E ratio. As the outstanding stock of Teva Pharmaceutical Industries Limited NYSE:TEVA Drug Manufacturers – Other is bought and sold in the stock market, the current market cap indicates the existing public opinion of the net worth of Teva Pharmaceutical Industries Limited TEVA Drug Manufacturers – Other.
The deal was announced more than a year ago and had been expected to wrap up last month, but it has taken longer as the companies have arranged sales of more drugs than anticipated to clear the antitrust regulators.
Several research firms have weighed in on TEVA.
On 7/11/2016, Teva Pharmaceutical Industries Limited (NYSE:TEVA) finished the previous buying and selling session with the price of $50.93.
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) issued an update on its FY16 earnings guidance on Wednesday morning.
The Israeli pharmaceutical company now expects to report adjusted earnings between $1.19 and $1.22 per share, up from its previous forecast for between $1.16 and $1.20 per share. Citigroup Inc. reissued a buy rating and issued a $75.00 target price on shares of Teva Pharmaceutical Industries in a research report on Thursday, April 21st. 11 said it’s a Buy, 5 assigned Hold rating where 0 stated the stock as Underperform and 0 marked the stock as Sell.
But in an emailed statement on Wednesday, the company backed Teva’s view of the timing on the closing and an Allergan spokesman said that approval was “imminent”.
Separately, TheStreet Ratings team rates the stock as a “buy” with a ratings score of B. The Firm operates through two divisions: Generic medicines and Specialty medicines.